drugset / Trial / NCT01129063

Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects

NCT01129063

Phase 1 Completed 32 enrolled Sanofi Bristol-Myers Squibb · collab
CrossoverOpen-labelBasic science

Summary

The objectives of the study are to: * Assess the within-subject variability of the pharmacokinetic profiles of the clopidogrel and its active metabolite after a replicated single administration of 75 mg of clopidogrel in healthy male and female subjects * Assess the pharmacokinetic profiles of the clopidogrel and its active metabolite after single administration of 75 or 300 mg of clopidogrel

Timeline

Start
2009-03
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral
Subject Clopidogrel Small molecule 300 mg Oral

Indications

No indication recorded.